¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"prostatic specific antigen"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • specific serum
    ƯÀÌÇ÷û
  • specific soluble substance
    ƯÀ̰¡¿ë¹°Áú
  • stage-specific protein
    ¹ßÀ°´Ü°èƯÀ̴ܹéÁú
  • antigen
    Ç׿ø
  • antigen analysis
    Ç׿øºÐ¼®
  • antigen binding capacity
    Ç׿ø°áÇÕ´É
  • antigen binding fragment
    Ç׿ø°áÇÕºÎÀ§
  • antigen binding receptor
    Ç׿ø°áÇÕ¼ö¿ëü
  • antigen capture assay
    Ç׿øÆ÷È¹ÃøÁ¤
  • antigen competition
    Ç׿ø°æÀï
  • antigen diffusion constant
    Ç׿øÈ®»ê»ó¼ö
  • antigen excess
    Ç׿ø°úÀ×
  • antigen excess zone
    Ç׿ø°úÀ×±¸¿ª
  • antigen mimicry
    Ç׿øÀ¯»ç¼º
  • antigen modification
    Ç׿øº¯È­, Ç׿ø¼ö½Ä
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • specific soluble substance
    ƯÀ̰¡¿ë¹°Áú
  • virus-specific
    ¹ÙÀÌ·¯½ºÆ¯ÀÌ-
  • antigen
    Ç׿ø
  • accessible antigen
    Á¢±Ù°¡´ÉÇ׿ø
  • antigen competition
    Ç׿ø°æÀï
  • antigen excess
    Ç׿ø°úÀ×
  • antigen mimicry
    Ç׿øÀ¯»ç¼º
  • antigen modification
    Ç׿øº¯È­, Ç׿ø¼ö½Ä
  • antigen presentation
    Ç׿øÀü´Þ
  • antigen receptor
    Ç׿ø¼ö¿ëü
  • antigen recognition
    Ç׿øÀÎÁö
  • antigen analysis
    Ç׿øºÐ¼®
  • antigen capture assay
    Ç׿øÆ÷È¹ÃøÁ¤
  • antigen binding capacity
    Ç׿ø°áÇÕ´É
  • antigen binding fragment
    Ç׿ø°áÇÕºÎÀ§
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • prostatic venous plexus
    Àü¸³»ùÁ¤¸Æ¾ó±â
  • prostatic vesicle
    Àü¸³¼±¼Ò¼öÆ÷(îñí¡àÍá³â©øÞ)
  • ABH antigen
    ABH Ç׿ø
  • B antigen
    B Ç׿ø(ù÷ê«)
  • B cell antigen
    B ¼¼Æ÷Ç׿ø
  • CA 19-9 antigen
    CA 19-9 Ç׿ø
  • CA 50 antigen
    CA 50 Ç׿ø
  • CA-2<>
    CA-2<<ÄÝ·ÎÀ̵åÇ׿ø>>
  • CD5 antigen
    CD5 Ç׿ø
  • CEA(carcinoembryonic antigen)
    žƼº¾ÏÇ׿ø
  • Cartwright antigen
    īƮ¶óÀÌÆ®Ç׿ø
  • Cha antigen
    Cha Ç׿ø
  • Chido (Ch") antigen
    Chido(Ch") Ç׿ø
  • D antigen
    D Ç׿ø
  • D antigen
    DÇ׿ø
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • prostatic sinus
    Àü¸³»ùµ¿, Àü¸³¼±µ¿.
  • prostatic urethra
    Àü¸³»ù¿äµµ(¡­èñÔ³), Àü¸³¼±¿äµµ.
  • prostatic urethra
    Àü¸³¼±¿äµµ
  • prostatic urinary sphincter
    Àü¸³¼± ¿äµµ°ý¾à±Ù
  • prostatic utricle
    Àü¸³»ù¼Ò½Ç(¡­á³ãø) ³²¼ºÀڱà , Àü¸³¼±¼Ò½Ç.
  • prostatic utricle
    Àü¸³»ù¼Ò½Ç
  • prostatic utricle
    Àü¸³»ù¼Ò½Ç(¡­á³ãø) ³²¼ºÀÚ?, Àü¸³¼±¼Ò½Ç. ?ÇØºÎ
  • prostatic utricle
    Àü¸³¼±¼Ò½Ç
  • prostatic venous plexus
    Àü¸³»ùÁ¤¸Æ¾ó±â
  • prostatic vesicle
    Àü¸³¼±¼Ò¼öÆ÷(îñí¡àÍá³â©øÞ)
  • transurethral prostatic resection
    °æ¿äµµÀü¸³¼±ÀýÁ¦¼ú(¡­îñí¡àÍôîð¶âú).
  • age specific death rate
    ¿¬·Éº° »ç¸Á·ü
  • blood group specific substance
    Ç÷¾×ÇüƯÀ̹°Áú.
  • bulk specific gravity
    ¿ëÀûºñÁß(é»îÝÝïñì)
  • donor-specific phage
    °ø¿©±ÕƯÀÌÆÄÁö
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • Ia antigen
    Ia Ç׿ø(ù÷ê«)
  • incomplete antigen
    ºÒ¿ÏÀü Ç׿ø(ÝÕèÇîïù÷ê«)
  • K antigen
    K Ç׿ø
  • LS antigen
    LS Ç׿ø(ù÷ê«)
  • M antigen
    M Ç׿ø(ù÷ê«)
  • MHC antigen
    MHCÇ׿ø(ù÷ê«)
  • NP antigen
    NPÇ׿ø(ù÷ê«)
  • O antigen
    O Ç׿ø(ù÷ê«)
  • P antigen
    P
  • particulate antigen
    ÀÔÀÚ Ç׿ø(Ø£í­ù÷ê«)
  • penton antigen
    ÆæÅæ Ç׿ø(ù÷ê«)
  • protective antigen
    º¸È£ Ç׿ø(ÜÁûÞù÷ê«)
  • R antigen
    R Ç׿ø(ù÷ê«)
  • S antigen
    S Ç׿ø(ù÷ê«)
  • SH-antigen
    SH-Ç׿ø(ù÷ê«)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
PIF paratoid isoelectric focusing variant protein; peak inspiratory flow; proinsulin-free; prolactin-inh...
PM after death (Lat. post mortem); after noon [Lat. post meridiem]; mean pressure; pacemaker; pantomogr...
pros prostate, prostatic
PRPS prostatic secretory protein
PS pacemaker syndrome; paired stimulation; paradoxical sleep; paraspinal; parasympathetic; Parkinson sy...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
PAP Prostatic Acid Phosphatase
PBP Prostatic Binding Protein
PIN Prostatic Intraepithelial Neoplasia
PAcP Prostatic acid phosphatase
PC Prostatic cancer
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • endogenous antigen
    ³»ºÎ Ç׿ø
    µ¿¹°ÀÇ Ã¼³»¿¡ Á¸ÀçÇÏ´Â °Íµé·Î¼­ µ¿¹°ÀÇ Á¶Á÷, ¼¼Æ÷ÀÇ ÀϺΠ±¸¼º ¼ººÐ µîÀÌ ¿©±â¿¡ ¼ÓÇÑ´Ù.
  • ensitization 1. administration of antigen to induce a primary immune response; priming; immunization. 2. exposure to allergen that results in the development of hypersensitivity. 3. the coating of erythrocytes with antibody so that they are subject to lys
    ³»¹ø
    ƯÈ÷ ¾È°Ë ¿¬ÀÇ.
  • fetal antigen
    ÅÂ¾Æ Ç׿ø
    Á¾¾ç °ü·Ã Ç׿øÀÇ ÀÏÁ¾, Å»ý±â Á¶Á÷¿¡¼­´Â ÀÎÁ¤µÇÁö¸¸, Á¤»óÀûÀÎ ºÐÈ­¸¦ ¹âÀº Á¶Á÷¿¡¼­´Â ÀÎÁ¤µÇÁö ¾Ê°Å³ª ±ØÈ÷ ¹Ì·® Á¸ÀçÇϰųª ÇÑ´Ù.
  • H antigen
    H Ç׿ø
    1. ¿îµ¿¼º ¼¼±ÕÀÇ Æí¸ð Ç׿ø 2. H-¹°Áú.
  • H-2 antigen
    H-2 Ç׿ø
  • heterologous antigen
    ÀÌÁ¾ Ç׿ø
  • HL-A type antigen
    ¿¡ÀÌÄ¡¿¤¿¡ÀÌ Ç׿ø
    »ç¶÷ÀÇ ÀûÇ÷±¸ ÀÌ¿ÜÀÇ ¸ðµç ¼¼Æ÷°¡ °¡Áö°í ÀÖ´Â Ç׿ø. »ç¶÷ ¹éÇ÷±¸ Ç׿øÀ̶ó°íµµ ÇÑ´Ù. H´Â »ç¶÷
  • homologous antigen
    »óµ¿ Ç׿ø
  • human histocompatibility antigen
    ÀÎü Á¶Á÷ ÀûÇÕ Ç׿ø
  • human leukocyte antigen-B27
    ÀÎü ¹éÇ÷±¸ Ç×ü-B27
    º¸Åë °­Á÷¼º ôÃß¿° ȯÀÚ¿¡¼­ ³ªÅ¸³ª´Â À¯Àü Ç¥½ÃÀÚ.
  • lymphocyte defined antigen
    ¸²ÇÁ±¸ ±ÔÁ¤ Ç׿ø
  • N-antigen
    N Ç׿ø
  • nuclear antigen
    ÇÙ Ç׿ø
  • pancreatic oncofetal antigen
    ÃéÀåÀÇ Å¾Ƽº ¾Ï Ç׿ø
  • pollen antigen
    ²É°¡·ç Ç׿ø, È­ºÐ Ç׿ø
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
specific capsular substance A soluble type-specific polysaccharide produced during active growth of virulent pneumococci composing a large part of the capsule.
Synonym: pneumococcal polysaccharide, soluble specific substance, specific soluble polysaccharide, specific soluble sugar.
(05 Mar 2000)
specific cause A cause the action of which definitely produces the condition in question.
(05 Mar 2000)
specific cholinesterase <enzyme, neurology, physiology> An enzyme that breaks down unused acetylcholine in the synaptic cleft (the space between neurons), this enzyme is necessary to restore the synaptic cleft so it is ready to transmit the next nerve impulse.
(06 May 1997)
specific compliance The compliance of a structure divided by its initial volume, more specifically for the lungs, the compliance divided by the functional residual capacity.
(05 Mar 2000)
specific disease A disease produced by the action of a special pathogenic microorganism.
(05 Mar 2000)
specific dynamic action The increase of heat production caused by the ingestion of food, especially of protein.
(05 Mar 2000)
specific epithet The label (or designation) of a particular species in the binomial nomenclature system. For example: coli is the specific epithet of Escherichia coli.
(09 Oct 1997)
specific extinction Absorbance (of light) per unit path length (usually the centimeter) and per unit of mass concentration.
Compare: molar absorption coefficient.
Synonym: absorbancy index, absorptivity, extinction coefficient, specific extinction.
(05 Mar 2000)
specific granule One of the two main classes of granules found in neutrophils: contain lactoferrin, lysozyme, Vitamin B12 binding protein and elastase. Are released more readily than the azurophil (primary) granules which have typical lysosmal contents.
(18 Nov 1997)
specific gravity A measure of concentration. It is the weight of a substance, as compared (as a ratio) with that of an equal volume of water.
(27 Sep 1997)
specific haemolysin A sensitizing, complement-fixing, haemolytic antibody that reacts totally or completely with red blood cells of the antigenic type used to stimulate the formation of the haemolysin.
(05 Mar 2000)
specific heat The amount of energy (measured in calories or joules) needed to raise thetemperature of one gram of a pure substance by one degree C.
(09 Oct 1997)
specific heat capacity <chemistry> The amount of energy required to raise the temperature of one gram of a substance by one degree Celsius (or Kelvin).
(09 Jan 1998)
specific immune globulin Globulin fraction of pooled serums (or plasma) selected for high titre of antibodies specific for a particular antigen, or from persons specifically immunised.
(05 Mar 2000)
specific immunity The immune status in which there is an altered reactivity directed solely against the antigenic determinants (infectious agent or other) that stimulated it.
See: acquired immunity.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 5
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 5
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 5
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 5
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 5
ÅëÇÕ°Ë»ö ¿Ï·á